See every side of every news story
Get Started
SubscribeLogin
Pope Francis
Vatican
Volodymyr Zelenskyy
Ukraine War
Olaf Scholz
Donald Trump
Elon Musk
Israel-Hamas Conflict
Basketball
Vladimir Putin
Manchester City
Hamas
Published • loading... • Updated

FDA Approves Genentech’s Evrysdi Tablet as First and Only Tablet for Spinal Muscular Atrophy (SMA) - Pipelinereview

Summary by Pipelinereview
– Evrysdi is the only non-invasive disease-modifying SMA treatment and is approved in over 100 countries – – Evrysdi tablet can be stored at room temperature and offers the same demonstrated efficacy and safety as the currently available oral solution – – New tablet formulation may provide greater freedom and independence for people with SMA thanks to simplified dose administration – SOUTH SAN FRANCISCO, CA, USA I February 12, 2025 I Genentech, …
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

2 Articles

All
Left
Center
Right
pipelinereviewpipelinereview

FDA Approves Genentech’s Evrysdi Tablet as First and Only Tablet for Spinal Muscular Atrophy (SMA) - Pipelinereview

– Evrysdi is the only non-invasive disease-modifying SMA treatment and is approved in over 100 countries – – Evrysdi tablet can be stored at room temperature and offers the same demonstrated efficacy and safety as the currently available oral solution – – New tablet formulation may provide greater freedom and independence for people with SMA thanks to simplified dose administration – SOUTH SAN FRANCISCO, CA, USA I February 12, 2025 I Genentech, …

Read Full Article
Cure SMACure SMA

FDA Approves Genentech's Evrysdi Tablet as First and Only Tablet for Spinal Muscular Atrophy (SMA)

“Evrysdi has robust potential to modify the SMA disease trajectory, and has already been used to treat thousands of patients to date. This approval marks another significant step forward,” said Levi Garraway, M.D., Ph.D., Genentech’s Chief Medical Officer and Head of Global Product Development. “The Evrysdi tablet combines established efficacy with convenience, providing an additional flexible option for SMA management.” …

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Cure SMA broke the news in on Wednesday, February 12, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

FDA

FDA

South San Francisco

South San Francisco

News
For You
Search
BlindspotLocal